Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type‐2 diabetes

Abstract

In the present study, resveratrol, a polyphenolic SIRT1 activator was evaluated for its SIRT1 activation in an in vitro fluorescent based assay (EC(50) : 7 μM). The efficacy of resveratrol was also evaluated in ob/ob mice for its antidiabetic and associated metabolic effects. Mice aged 5-8 weeks were included in four groups; control and resveratrol at 5, 15, 50 mg/kg, b.i.d. and were dosed orally. After 4 weeks of drug treatment, body weights were noted and random blood glucose and insulin was estimated for the antidiabetic effect. Animals were also subjected to the oral glucose tolerance test to observe any improvement in the glucose excursion. Triglycerides, total cholesterol, adiponectin and free fatty acid levels were also estimated. The results showed that resveratrol exhibited significant antihyperglycemic activity with an improvement in the insulin levels compared with the control mice. There was also a significant improvement observed in the glucose excursion in the oral glucose tolerance test performed for 120 min; although an insignificant improvement in the triglycerides, total cholesterol, adiponectin and free fatty acid levels was observed at different doses of resveratrol tested. The present findings suggest that resveratrol is an antihyperglycemic agent and drugs similar to resveratrol can be considered as an effective therapeutic adjuvant for the current treatment of diabetes mellitus.

Bioinformatics analysis of abnormal DNA methylation in muscle samples from monozygotic twins discordant for type 2 diabetes

“…The significantly hyper-and hypo-methylated genes identified in the current study may provide several novel candidate genes associated with the occurrence of T2D. SIRT1, an NAD(+)-dependent histone deacetylase, which was hyper-methylated according to the present results, was observed to regulate glucose/lipid metabolism through its deacetylase activity on numerous substrates (21,22). In addition, SIRT1 positively regulates insulin secretion in pancreatic β cells (23), and protects cells from oxidative stress and inflammation.…”

The combination of resveratrol and conjugated linoleic acid is not useful in preventing obesity

“…Nevertheless, this effect has been mainly observed in mice [23]. Meanwhile, it has been suggested that resveratrol improves insulin action [27,28,30]. Thus, it could be hypothesized that by administering both [7].…”

Resveratrol reduces lipid peroxidation and increases sirtuin 1 expression in adult animals programed by neonatal protein restriction

“…Thus, the antioxidant effect of resveratrol in LPHC does not seem to be consequent to glucose homeostasis improvement. The ability of resveratrol to reduce insulin levels and hyperglycemia was reported in several studies including streptozotocin-and nicotinamide-induced experimental diabetic rats (Palsamy & Subramanian 2008, Ramadori et al 2009, Sharma et al 2010. However, these effects of resveratrol seemed to occur in animals that had impaired glucose homeostasis.…”